Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

PureTech (PRTC) Share Price

Price 124.00p on 12-11-2026 at 19:15:11
Change -2.00p -1.59%
Buy 125.20p
Sell 124.80p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 1,146.00 at 124.00p
Day's Volume: 335,586
Last Close: 124.00p
Open: 126.40p
ISIN: GB00BY2Z0H74
Day's Range 123.80p - 128.40p
52wk Range: 106.60p - 142.00p
Market Capitalisation: £304.02m
VWAP: 126.13823p
Shares in Issue: 245.18m

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Small Cap, FTSE Small Cap ex Investment Trusts

PureTech (PRTC) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 1,146 124.00p Automatic Execution
 16:35:04 - 12-Nov-26
Sell* 71,677 124.00p Uncrossing Trade
 16:35:04 - 12-Nov-26
Sell* 112 124.80p Automatic Execution
 16:27:20 - 12-Nov-26
Sell* 300 124.80p Automatic Execution
 16:27:19 - 12-Nov-26
Sell* 300 124.80p Automatic Execution
 16:27:18 - 12-Nov-26
Sell* 61 124.80p Automatic Execution
 16:27:17 - 12-Nov-26
Sell* 239 124.80p Automatic Execution
 16:27:17 - 12-Nov-26
Sell* 52 124.80p Automatic Execution
 16:27:17 - 12-Nov-26
Sell* 299 125.00p Automatic Execution
 16:11:13 - 12-Nov-26
Sell* 24 124.60p SI Trade
 16:11:07 - 12-Nov-26
See more PureTech trades

PureTech (PRTC) Share Price History

Time period:
to
Date Open High Low Close Volume
12th Nov 2026 (Thu) 126.40 128.40 123.80 124.00 335,586
11th Nov 2026 (Wed) 123.70 126.00 123.60 126.00 1,425,929
10th Nov 2026 (Tue) 117.00 124.00 117.00 122.40 926,398
9th Nov 2026 (Mon) 119.60 121.60 119.20 119.60 153,919
6th Nov 2026 (Fri) 120.00 120.20 117.00 119.40 402,144
5th Nov 2026 (Thu) 124.00 125.20 121.60 121.80 300,299
4th Nov 2026 (Wed) 123.00 126.60 122.80 124.20 324,143
3rd Nov 2026 (Tue) 118.60 124.00 118.00 124.00 641,878
2nd Nov 2026 (Mon) 118.00 119.80 117.20 119.40 305,979
30th Oct 2026 (Fri) 116.00 118.00 115.00 117.40 450,974
29th Oct 2026 (Thu) 117.80 118.00 115.60 117.60 383,860
28th Oct 2026 (Wed) 117.60 118.80 115.40 117.60 426,570
27th Oct 2026 (Tue) 113.60 119.20 113.60 118.00 609,306
26th Oct 2026 (Mon) 110.00 117.00 110.00 114.00 474,532
23rd Oct 2026 (Fri) 114.80 116.00 110.00 110.00 265,765
22nd Oct 2026 (Thu) 116.00 116.00 113.60 115.80 148,690
21st Oct 2026 (Wed) 110.00 114.40 110.00 114.40 172,886
20th Oct 2026 (Tue) 110.00 113.80 110.00 113.80 281,792
19th Oct 2026 (Mon) 112.00 115.40 112.00 115.40 275,156
16th Oct 2026 (Fri) 112.00 115.00 112.00 114.60 935,544
15th Oct 2026 (Thu) 112.40 114.80 112.40 114.00 506,794
14th Oct 2026 (Wed) 112.60 114.20 112.40 113.80 397,574
13th Oct 2026 (Tue) 109.00 114.40 109.00 111.80 454,410
See more PureTech price history

PureTech (PRTC) Regulatory News

Date Source Headline
12th Nov 2026 6:00 pm RNS Holding(s) in Company
30th Oct 2026 5:40 pm RNS Holding(s) in Company
30th Oct 2026 7:00 am RNS-R PureTech Health Wins 2026 Prix Galien USA Award
29th Oct 2026 11:00 am RNS-R PRTC's Celea Appoints Paul Audhya, MD, MBA, as CMO
26th Oct 2026 7:00 am RNS-R PRTC's Gallop Presents Ph1b LYT-200 Data at ESMO
19th Oct 2026 7:00 am RNS-R PRTC's Gallop to Present Ph1b LYT-200 Data at ESMO
9th Oct 2026 6:00 pm RNS-R PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP
7th Oct 2026 6:00 pm RNS-R PRTC's SPTX: Phase 2a Trial of GlyphAgo Initiated
7th Oct 2026 7:00 am RNS Holding(s) in Company
25th Sep 2026 6:13 pm RNS Holding(s) in Company
See more PureTech regulatory news

PureTech (PRTC) Share News

IN BRIEF: PureTech Health to announce clinical trial results in Madrid

19th Oct 2026 08:56

PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical company - Announces results from the first phase of the clinical trial of LYT-200, which will be presented at the European Society for Medical Oncology. LYT-200 is an antibody treatment designed to help the immune system recognise and fight cancer more effectively. The presentation will take place on October 23 in Madrid. Head of Oncology at PureTech and Chief Medical Officer Aleksandra Filipovic says: "Phase 1b results provide a strong foundation for the continued development of LYT-200." Read More

TRADING UPDATES: Dillistone new strategy; Oriole Resources maiden MRE

7th Oct 2026 21:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

PureTech swings to first-half profit as investment gains soar

22nd Sep 2026 12:42

(Alliance News) - PureTech PLC on Tuesday hailed "significant progress" across its portfolio as it swung to a first-half profit. Read More

PureTech Health says US FDA progress provides clear path for LYT-200

21st Sep 2026 10:34

(Alliance News) - PureTech Health PLC on Monday said feedback from the US Food & Drug Administration supports the advancement of its blood cancer treatment, LYT-200. Read More

UK earnings, trading statements calendar - next 7 days

15th Sep 2026 14:30

Read More

See more PureTech news
FTSE 100 Latest
Value10,863.09
Change27.62

Login to your account

Forgot Password?

Not Registered